Business Description
Acorda Therapeutics Inc
NAICS : 325414
SIC : 2836
ISIN : US00484M1062
Share Class Description:
STU:CDG: Ordinary SharesDescription
Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis. The company's Net product revenue is derived from the sales of Ampyra and Inbrija.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.37 | |||||
| Equity-to-Asset | 0.51 | |||||
| Debt-to-Equity | 0.22 | |||||
| Debt-to-EBITDA | -0.26 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | -33.04 | |||||
| Beneish M-Score | -3.35 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -37 | |||||
| 3-Year EBITDA Growth Rate | -28.4 | |||||
| 3-Year EPS without NRI Growth Rate | 48.1 | |||||
| 3-Year FCF Growth Rate | 58.6 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.82 | |||||
| Quick Ratio | 1.79 | |||||
| Cash Ratio | 0.98 | |||||
| Days Inventory | 514.55 | |||||
| Days Sales Outstanding | 59.24 | |||||
| Days Payable | 346.21 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -37.9 | |||||
| Shareholder Yield % | -28535.29 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 87.54 | |||||
| Operating Margin % | -7.72 | |||||
| Net Margin % | -320.09 | |||||
| FCF Margin % | -37.19 | |||||
| ROE % | -1800.75 | |||||
| ROA % | -78.69 | |||||
| ROIC % | -1.52 | |||||
| ROC (Joel Greenblatt) % | -2506.37 | |||||
| ROCE % | -137.6 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -0.15 | |||||
| EV-to-EBITDA | -0.16 | |||||
| EV-to-Revenue | 0.54 | |||||
| EV-to-FCF | -1.44 | |||||
| Earnings Yield (Greenblatt) % | -666.67 | |||||
| FCF Yield % | -159711.76 | |||||
| Forward Rate of Return (Yacktman) % | -1964290.09 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Acorda Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 66.892 | ||
| EPS (TTM) (€) | -171.221 | ||
| Beta | 3.03 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0 | ||
| 20-Day SMA (€) | 9.36 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 9.36 - 9.36 | ||
| Shares Outstanding (Mil) | 1.24 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Acorda Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Acorda Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Acorda Therapeutics Inc Frequently Asked Questions
What is Acorda Therapeutics Inc(STU:CDG)'s stock price today?
The current price of STU:CDG is €9.36. The 52 week high of STU:CDG is €9.36 and 52 week low is €9.36.
When is next earnings date of Acorda Therapeutics Inc(STU:CDG)?
The next earnings date of Acorda Therapeutics Inc(STU:CDG) is 2024-12-25 Est..
Does Acorda Therapeutics Inc(STU:CDG) pay dividends? If so, how much?
Acorda Therapeutics Inc(STU:CDG) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers